Product Description
pegylated recombinant human arginase for children and young people with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade gliomas (brain cancers). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03455140)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bio-Cancer Treatment International Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Hepatocellular Carcinoma|Glioma|Brain Cancer|Leukemia|Neuroblastoma|Sarcoma|Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PARC | P2 |
Completed |
Acute Myeloid Leukemia |
2022-07-22 |
|
PARC | P2 |
Unknown status |
Sarcoma|Glioma|Leukemia|Neuroblastoma|Brain Cancer |
2021-05-01 |
|
BCT-100-007 | P2 |
Unknown status |
Acute Myeloid Leukemia |
2019-09-01 |
|
BCT-100-006 | P2 |
Completed |
Hepatocellular Carcinoma |
2017-03-01 |
55% |